Objective: Differences in disease outcomes between users and nonusers of hormone therapy (HT) and between users of estrogen therapy (ET) and users of estrogen + progesterone therapy (EPT) may relate to differences in serum hormone concentrations between these populations. In this study, we examined the response of serum hormone levels in healthy postmenopausal women after 1 year of HT.
D uring the menopausal transition, the ovarian production of estrogen and progesterone declines. This natural endocrine transition is associated with dimin-ished circulating levels of estrone (E 1 ), estradiol (E 2 ), and sex hormoneYbinding globulin (SHBG) and with an increase in levels of follicle-stimulating hormone (FSH) and luteinizing hormone. 1 The use of exogenous hormones has been reported to increase the levels of circulating estrogens and SHBG. 2 Prospective data on the response of serum hormone levels to hormone therapy (HT) in healthy postmenopausal women are sparse. Much of our existing knowledge about hormone changes at the menopausal transition and beyond comes from cross-sectional studies of premenopausal and postmenopausal women. There are relatively few longitudinal studies of levels of estrogens in women as they pass through the menopausal transition. 1, 3 Several more recent cross-sectional studies have examined differences in postmenopausal endogenous hormones by characteristics such as race/ethnicity; 4, 5 in addition, a few studies have examined the relationship between endogenous hormone levels and specific disease outcomes, such as breast cancer 6, 7 and hip fracture. 8 There have been relatively few studies that have prospectively evaluated hormone levels in women using exogenous HTs, 9<12 and these have generally been small.
Recent evidence, including that from the Women's Health Initiative (WHI), has demonstrated significant differences in disease outcomes between users and nonusers of HT that differed between estrogen + progesterone therapy (EPT) and estrogen therapy (ET). 13, 14 It is reasonable to hypothesize that these differences relate to variations in serum sex hormone concentrations between users and nonusers of HT and suggest that serum hormone responses may differ between users of ET and EPT. However, the physiological implications of variations in serum hormone levels (both endogenous and as the result of exogenous hormone administration) are still being clarified. A better understanding of the response of basic serum hormone levels to HT in healthy postmenopausal women will help inform research examining specific HT regimens and disease risk.
The WHI prospective, randomized, longitudinal controlled clinical trials of HT offer an unprecedented opportunity to examine the changes in sex steroid milieu in response to HT and to determine if the response differs with the addition of a progestin. We now report the magnitude of response of E 1 , E 2 , free E 2 , bioavailable E 2 , SHBG, and progesterone to HT in a representative subgroup of healthy, adherent, postmenopausal participants selected from each of the randomized HT assignments. In addition, the results will be further examined by age, body mass index (BMI), oophorectomy status, race, smoking status, report of vasomotor symptoms, and baseline sex hormone levels to determine whether serum hormone responses vary significantly according to these variables.
METHODS

Study population
The WHI is a multicenter prospective study of postmenopausal women's health involving more than 160,000 postmenopausal women between the ages 50 to 79 years enrolled in either an observational study (n = 93,676) or one or more of four randomized controlled clinical trials. The WHI hormone trials comprised two parallel trials testing the effects of EPT in 16,608 women who had an intact uterus at baseline and the effects of ET in 10,739 women who had no uterus at baseline. Participants in the EPT arm were randomized to receive 0.625 mg of conjugated equine estrogens (CEE) plus 2.5 mg of medroxyprogesterone acetate (MPA) daily (Prempro; Wyeth, Philadelphia, PA) or a daily placebo pill. Participants in the ET arm were randomized to receive either 0.625 mg of CEE daily (Premarin; Wyeth) or a daily placebo pill. Participants using HT before study enrollment underwent a 3-month washout period before starting study therapy or placebo. A description of the study and rationale has been reported elsewhere. 15 The study was approved by the investigators' institutional review boards, and each participant signed a written informed consent form to participate in the study.
Selection of women from the active arms of HT trials and controls
Of the 27,237 participants in the HT trials, 9,810 met the eligibility criteria. These criteria were designed to identify a group of adherent participants representing a range of age and weight categories while ensuring prudent use of stored serum samples within the WHI. Participants who were selected had excellent adherence to the assigned treatment arm during the first year of the study (defined as taking Q90% of the assigned study pills during the first year of the study and no use of HT for those randomized to placebo), at least 4 mL available fasting serum for baseline and year 1 visits, and no missing values for BMI. Women were excluded if they had a diagnosis of cardiovascular disease, cancer on fracture or died during a mean (SD) of 8.1 (1.5) years of follow-up.
From the subgroup of eligible women, 200 women were randomly selected. These included 50 each from the active and placebo arms, with a specified number of women selected in age and BMI categories. Specifically, three, four, and three women with screening ages of 50 to 59, 60 to 69, and 70 to 79 years, respectively, were selected in each of the BMI (kilograms/meters squared) categories of less than 25.0 kg/m 2 (underweight/normal), overweight I (25.0-29.9 kg/m 2 ), obesity I (30.0-34.9 kg/m 2 ), obesity II (35.0-39.9 kg/m 2 ), and extreme obesity (Q40 kg/m 2 ), in each of the four active and placebo groups.
Blood samples and measurement of sex hormones and SHBG
Blood was collected from each study participant at the baseline visit and after 1 year of randomization following at least a 12-hour fast and was then stored at j70-C. On average, participants had their baseline blood draw 75 days (SD, 37 days) before initiating study pills, and 367 days (SD, 22 days) elapsed between the initiation of study pills and the year 1 follow-up blood draw. Samples were shipped on dry ice to the Reproductive Endocrine Research Laboratory (University of Southern California, Los Angeles, CA). Laboratory personnel were blinded to treatment status, and specimens were randomly ordered and sent to the laboratory in batches that included blind duplicate and pooled quality control samples. E 1 , E 2 , and progesterone (the latter in EPT participants only) were quantified by radioimmunoassay after a hexane-ethyl acetate extraction. Intra-assay coefficients of variation ranged from 4.1% to 7.7% for the assays, with interassay coefficients of variation ranging from 5.8% to 13%. SHBG was assayed via a solid-phase, twosite chemiluminescent immunoassay using an Immulite analyzer (Siemens Healthcare Diagnostics, Deerfield, IL). Free E 2 (nonalbumin or SHBG bound) and bioavailable E 2 (non-SHBG bound) values were calculated based on a validated algorithm using measured values for E 2 and SHBG and an average value for albumin. The sensitivity of the E 2 assay was 3 pg/mL (11.0 pmol/L), and concentrations below these values were deemed undetectable.
Statistical analyses
We compared log-transformed sex hormone levels at year 1 in relation to HT randomization assignment using linear regression models adjusted for age, BMI, smoking status, and log-transformed baseline sex hormone levels. In addition, we calculated ratios of year 1 to baseline levels for each woman to estimate the relative change.
To examine subgroup effects for each sex hormone, we tested whether the main effects of EPT and ET differed. If no significant differences were found, we pooled the two active arms (CEE active and CEE + MPA active) and the two placebo arms and fit linear regression models, testing one at a time, to determine whether the HT effect was modified by age, BMI, race, smoking status, baseline sex hormone levels, self-report of vasomotor symptoms at baseline, and oopho-rectomy. For age, BMI, and baseline sex hormone levels, we used a 1-degree-of-freedom test for trend.
Comparisons of baseline characteristics by randomization assignment were made by Fisher's exact test of association and two-sample t tests. Geometric means are presented for biomarkers. All analyses were done in SAS version 9.1.3, based on the intention-to-treat principle, and all statistical tests were two sided. All P values are nominal. Given the number of subgroup analyses performed, we can expect to have approximately two false-positives at the P = 0.05 level.
RESULTS
The baseline characteristics of all trial participants in the WHI EPT and ET trials are available. 15 Among the 200 women included in this study, the active study populations were similar to their corresponding placebo groups within the ET and EPT cohorts, with the exception of slightly more current smokers in the active EPT group relative to EPT placebo group (P = 0.05) and a trend toward more past smokers in the active ET group relative to the ET placebo group (P = 0.06; Table 1 ). Two women in the EPT trial had baseline progesterone values near 1,000 pg/mL (one in the active group and one in the placebo group); however, excluding these points did not change the overall pattern of response to exogenous progesterone, and, thus, these two participants were retained in the analysis.
Participants in this study had a mean (SD) age of 64.1 (7.6) years. Because women were selected by BMI status, the cohort in this study had higher average BMI (33.0 T 8.3 kg/m 2 ) and weight (85.8 T 21.4 kg) than did the overall WHI HT cohort (29.1 T 6.0 kg/m 2 and 76.2 T 17.0 kg, respectively). At baseline, the ET and EPT groups were similar in age, weight, BMI, ethnicity, report of vasomotor symptoms, and smoking status; however (as anticipated), women in the ET group were further from menopause and were substantially more likely to have had bilateral oophorectomy (38% of ET women relative to 0% of EPT women). The ET group also included significantly more women who reported ever using HT and significantly more reporting Bcurrent[ HT use before the 3-month washout period.
Baseline values for all of the measured hormones (SHBG, E 1 , E 2 , bioavailable E 2 , free E 2 , and progesterone) were comparable between the active and placebo groups at baseline. In contrast, there was a consistent trend toward higher estrogenic hormone values and slightly lower SHBG values in the ET group relative to the EPT group. For all participants, (geometric) mean baseline levels of E 2 (13.8 T 1.8 vs 11.1 T 1.7 pg/mL; P = 0.007), bioavailable E 2 (9.4 T 1.9 vs 7.5 T 1.9 pg/mL; P = 0.01), and free E 2 (0.37 T 1.90 vs 0.28 T 1.86 pg/mL; P = 0.003) were significantly higher in ET trial participants relative to EPT trial participants at baseline. The trends for E 1 (41.8 T 1.6 vs 39.7 T 1.5 ng/dL; P = 0.43) and SHBG (35.5 T 1.6 vs 39.0 T 1.6 nmol/L; P = 0.16) did not reach statistical significance.
The mean unadjusted hormone values for each treatment group are presented in Table 2 , with the ratio of active year 1 to baseline values presented in the right-hand column for each study arm (these are adjusted for log 2 baseline hormone values, age, BMI, and smoking status). The mean baseline SHBG concentration ranged from 35.1 nmol/L (ET placebo) to 40.8 nmol/L (EPT active). After 1 year of placebo, SHBG concentrations remained essentially unchanged. Women taking active hormone, however, saw a roughly 2.5-fold increase in serum SHBG concentration from baseline to 102.7 nmol/L in EPT participants and 90.7 nmol/L in ET participants. Values for the measured total estrogens (E 1 and E 2 ) followed a similar pattern (Table 2) , with a roughly fourfold increase in E 1 and a roughly threefold increase in total E 2 concentrations from baseline to year 1 in active hormone recipients. As expected, the increases in serum bioavailable and free E 2 concentrations were of a slightly smaller magnitude (approximately twofold increase relative to baseline).
Progesterone concentrations were assayed only for those women in the EPT trial. For women taking placebo, progesterone concentrations increased from 69.9 to 75.1 pg/mL. In contrast, measured serum progesterone concentrations for women taking active EPT decreased from 72.3 to 62.0 pg/mL. The corresponding ratio of change in the active group relative to the placebo group was 0.8 (95% CI, 0.7-0.9).
The effects of EPT did not differ from those of ET for the estrogenic hormones or SHBG (all P values 9 0.4), so for the subgroup analysis, the two active arms (ET and EPT) were combined for comparison with the pooled placebo arms. In multiple regression analysis, serum estrogenic hormone responses varied significantly by BMI, smoking status, age, black versus white race, report of vasomotor symptoms, and baseline hormone values (Table 3) . Heavier women had a smaller magnitude of serum estrogenic hormone response to exogenous hormone administration than did lighter-weight women. For example, compared with placebo, total E 1 levels increased with HT use 5.7 times for normal weight women and 3.2 times for obese women (P for interaction [P-int] G0.001). Similarly, bioavailable E 2 levels increased 2.5 times for normal weight women but only 1.8 times for obese women (P-int = 0.02).
Smoking status (never, past, or current) showed a graded relationship to an increase in estrogenic hormones (E 1 , total E 2 , and bioavailable E 2 ). Compared with placebo, the increase in E 1 for nonsmokers was 4.3 times; for past smokers, 3.4 times; and for current smokers, 2.1 times (P-int = 0.004). Similar differences were estimated for total E 2 and bioavailable E 2 .
Women with lower baseline hormone values had a larger relative response to exogenous hormones for all four estrogenic hormone assays evaluated. Adjusted mean total bioavailable E 2 concentrations increased 2.3-fold relative to baseline for women whose baseline bioavailable E 2 concentrations were in the lowest tertile, relative to 1.5-fold for women whose baseline concentrations were in the highest tertile (P = 0.003).
Older age was associated with a significantly greater response for E 1 (total) and total E 2 only; women 70 to 79 years old exhibited a 3.7-fold increase in total E 2 compared with a 2.4-fold increase in women 50 to 59 years old (P-int = 0.006). There was a suggestion that black women had a smaller magnitude of response of serum E 1 , total E 2 , bioavailable E 2 , and free E 2 . However, this trend reached statistical significance only for total E 2 , which increased 1.8 times in black women and 3.0 times in white women (P-int = 0.01). Women reporting vasomotor symptoms had a significantly smaller magnitude of response for all of the estrogenic hormone values tested and for SHBG. For example, the bioavailable E 2 level increased 2.1-fold among women with no vasomotor symptoms compared with 1.8-fold for women reporting mild and 1.4-fold among women reporting moderate to severe symptoms. In separate cross-tabulations, women with vasomotor symptoms were found to be younger than those without; however, the pattern of decreasing response to HT among women with vasomotor symptoms held within each age tertile (data not presented).
SHBG concentrations increased a total of 2.5-fold and varied significantly by participant race only, with black women exhibiting a lower overall magnitude of response to HT of 1.7-fold relative to 2.6-fold for white women. Progesterone concentrations decreased 0.8-fold relative to baseline after adjustment in recipients of EPT and did not vary significantly by any of the examined characteristics in the regression model. A history of bilateral oophorectomy did not significantly affect the magnitude of response of serum hormone levels to exogenous hormone administration for any of the hormones tested.
For a given covariate (such as age) and a specific hormone (such as total E 2 ), the relative magnitude of response to HT could vary because (1) the absolute values for that hormone varied according to that covariate at baseline, (2) that hormone varied according to that covariate at year 1, or (3) that hormone varied according to that covariate at both baseline and year 1. All three patterns were observed. For example, the different BMI groups demonstrated variation in total E 2 concentrations at baseline. Baseline total E 2 concentrations in the active hormone groups (ET and EPT combined) were 9.1, 11.1, and 13.6 pg/mL at baseline for women with a BMI less than 25, 25 to 39.9, or at least 30 kg/m 2 , respectively. By year 1, however, hormone values were more comparable across those BMI groups (30.2, 30.9, and 35.3 pg/mL, respectively). On the other hand, baseline concentrations of total E 2 were 12.4, 12.2, and 11.5 pg/mL among the age tertiles 50 to 59, 60 to 69, and 70 to 79 years (relatively similar), respectively; by year 1, these values were 28.6, 34.2, and 37.7 pg/mL, respectively. Lastly, in the case of smoking status, current smokers had both lower baseline hormone values (9.9 pg/mL relative to 12.5 and 11.9 pg/mL between never and past smokers, respectively) and a diminished response to HT (16.3 pg/mL relative to 39.8 and 32.6 pg/mL, respectively, after 1 y of therapy). Given that lower baseline hormone concentrations were associated with a greater magnitude of response to HT and that a number of the variables were associated with lower hormone levels at baseline (ie, lighterweight women had lower baseline estrogenic hormone concentrations), these analyses were repeated with correction for baseline hormone values. However, this correction did not substantially alter the findings.
DISCUSSION
Serum hormone responses in healthy, postmenopausal women taking exogenous hormones were similar among those taking EPT and ET. We observed a roughly fourfold increase in total E 1 and a roughly threefold increase in total E 2 concentrations from baseline to year 1 in active hormone recipients, with an increase in serum bioavailable and free E 2 concentrations of approximately twofold relative to baseline. The smaller magnitude increase in bioavailable and free serum E 2 concentrations is expected because a proportion of the increased value of the total serum hormone measurements reflects that proportion that is bound to SHBG, which is known to increase in the setting of HT 1 and which is not considered to be bioavailable. We observed a roughly 2.5fold increase in serum SHBG concentration relative to baseline for women taking active HT.
We did not observe significant changes in serum hormone concentrations from baseline to year 1 in women taking placebo, and in fact, the ratios of SHBG and the various estrogens from baseline to year 1 are nearly identical to those from year 1 in the active versus placebo groups. In the case of serum progesterone in women with a uterus, however, concentrations did tend to increase slightly from baseline to year 1 in participants taking placebo. The serum SHBG response was relatively comparable after 1 year of HT across all demographic characteristics (roughly 2.5-fold) and varied significantly only by race, with black women having a smaller SHBG and estrogenic hormone response than do white women. The relatively small subsample of women evaluated in this study did not allow for comparisons across other racial groups, and further study will also be necessary to evaluate the relative SHBG and estrogenic hormone response in other racial and ethnic groups.
The serum estrogenic hormone level response to exogenous HT also varied significantly by participant age, BMI, smoking status, report of vasomotor symptoms, and baseline hormone concentration. A larger response to HT was observed for women with lower BMI and in older women for all four estrogenic compounds assayed, with the greatest variability in the total hormone measurements. It might be expected that women with lower baseline hormone values would experience a larger increase in serum hormone concentrations, even if the absolute serum hormone concentrations were similar across these groups after therapy. This does seem to be the case, with a significantly greater magnitude of response of the estrogenic hormones observed for women in the lowest tertile of baseline hormone values relative to women in the highest tertile (P G 0.01; Table 3 ). Similarly, lighter-weight women and older women might be anticipated to have lower baseline hormone values, and therefore, a greater response to HT might be anticipated in these populations. Importantly, however, controlling for baseline hormone values did not significantly alter our findings, and the observed variations in serum hormone response to HT between subpopulations do not simply represent variations in hormone concentrations in these populations at baseline.
It is somewhat surprising that women reporting vasomotor symptoms at baseline had a smaller magnitude of response to HT than did women who did not report such symptoms. Previous work has shown that vasomotor symptoms correlate with lower estrogenic hormone levels and with higher FSH levels, with some evidence suggesting that it is the higher FSH level itself that may be the mediator of these symptoms. 16 We might have anticipated that women with vasomotor symptoms would have lower baseline hormone levels. We would therefore have anticipated a greater relative response to HT; however, this does not seem to be the case. It is possible that we are not fully correcting for a common factor underlying both increased self-report of vasomotor symptoms at baseline and decreased magnitude of response to exogenous hormones in our model. Because relief of vasomotor symptoms is one of the common indicators for initiating HT, further investigation into hormone levels before and after HT and their relationship to report of and relief of vasomotor symptoms is warranted.
Smoking status was a strong and consistent effect modifier of all measured serum estrogenic hormone levels. Current smokers had a significantly smaller response to hormone supplementation than did never smokers, with former smokers having intermediate levels. No effect of smoking was observed for either SHBG or progesterone. The effects of smoking on hormone metabolism are known to be complex and at least partially mediated by the hepatic P-450 enzyme system, and the physiological effects of HT are known to be diminished in smokers. 17 In postmenopausal women, the ovaries remain an important source of endogenous hormone production. In these postmenopausal women, history of bilateral oophorectomy did not impact serum hormone response to HT. It is impossible to evaluate the effects of hysterectomy separately from hormone preparation on response to supplementation in the current study because hysterectomized women receive a different hormone preparation than do women with an intact uterus. Baseline levels of estrogenic hormones were higher in the ET participants relative to the EPT participants, which may be related to the absence of a uterus in these women. On the other hand, women who have had a hysterectomy are known to differ in a number of demographic characteristics (higher rates of obesity, lower average socioeconomic status, etc) relative to those who have not, and these factors may contribute to the observed baseline hormone concentrations. Overall, serum hormone responses to therapy were similar among ET and EPT participants, suggesting that neither prior hysterectomy nor the addition of progesterone has an important impact on circulating estrogen levels in postmenopausal women using exogenous hormones.
Furthermore, the similar hormone responses among ET and EPT participants suggest that differences in serum hormone levels alone do not account, or do not fully account, for the differences in disease risk between women taking ET versus those taking EPT that have been observed in the WHI and in observational cohort studies. Although an evaluation of serum hormone response relative to specific disease risk is beyond the scope of the present study, such studies using WHI data and stored serum samples are ongoing. Available evidence from other recent studies, 18, 19 however, suggests that there is a modest increase in breast cancer risk among women with a high response of serum E 2 to HT, at least among some participant subgroups. The relatively similar hormone responses observed among ET and EPT women suggest that other factors may account for outcome differences between ET and EPT participants. For example, rather comprehensive analyses of serum proteomic changes between baseline and 1 year in the ET trial have recently been reported, 20 and analyses comparing ET and EPT proteomic changes are currently under journal review.
The greatest strengths of this study relate to the study design, including parallel randomized trials of ET and EPT and the ability to control for variables including age, BMI, smoking status, and race. The availability of pretreatment and posttreatment serum hormone values allows for a longitudinal examination of hormone levels in treated and in placebo control women. In addition, only adherent women were included in this study, which limits the potential for dilution of the treatment effect.
On the other hand, a relatively small subsample of women was selected for the measurement of serum hormone values, and serum hormone assays were limited to estrogens and SHBG, with progesterone assayed only in women in the EPT trial (women with a uterus, both active and placebo groups), limiting the interpretation of the progesterone findings. In addition, the timing of hormone dosing relative to blood collection at year 1 was not collected. However, the available literature 12 suggests limited fluctuations of plasma estrogen concentrations at steady state associated with hormone dosing, and any such fluctuation would not be expected to significantly affect either the mean hormone concentrations for active hormone participants at year 1 or the differential responses among participant subgroups. Measured serum progesterone concentrations 1 year after initiation of HT with EPT decreased modestly, whereas measured serum progesterone concentrations increased modestly in those on placebo. The corrected ratio of progesterone response to HT relative to placebo at 1 year was 0.8 (95% CI, 0.7-0.9), suggesting a slight but significant decrease in measured serum progesterone after 1 year of EPT.
This slight decrease in measured progesterone in women on CEE + MPA therapy is unexpected, and its significance is unclear. The concentration of serum progesterone as identified by the clinical or research laboratory may not accurately reflect the biological implications of exogenous progestin administration. Specifically, MPA is not detected by most progesterone assays, including the one used here. The undetected, exogenous progestin may suppress endogenous progesterone production, resulting in the decrease in detected progesterone. Alternatively, estrogen and/or progesterone administration could result in a decreased serum progesterone measurement via an alternate mechanism, such as decreased hepatic production of corticosteroid-binding globulin. Unfortunately, we do not know if similar decreases in progesterone levels are seen in women taking ET (as progesterone was assayed only in EPT trial participants). There is evidence that the biological effects of progesterone and MPA are similar, with similar (but not identical) effects on breast cancer risk. 21 Further study will be needed to clarify the effects of exogenous hormone administration on serum progestin levels and may indicate a need to assay both progesterone and the exogenous progestin (such as MPA) in future studies.
The primary objective of this study was to determine the magnitude of response of selected serum sex hormones to exogenous oral hormone treatment. The differential hormone responses observed for personal characteristics such as age, BMI, race, vasomotor symptoms, and smoking status were relatively unexpected, and the sample size in this study is not adequate to fully address all of the issues raised by these observations. A full understanding of how individual variables influence response to serum HT and its influence on health will require further study. The generally similar responses to serum hormone concentrations between ET and EPT may suggest that differences in outcomes between these two populations are the result of factors not directly mediated by serum hormone levels; however, further detailed analysis of serum hormone concentrations relative to specific disease outcomes will be necessary.
CONCLUSIONS
In postmenopausal women, circulating levels of estrogens and SHBG are increased by twofold to fourfold with the use of either ET or EPT. Circulating progesterone levels exhibit a modest but statistically significant reduction with the use of HT. Age, BMI, smoking status, report of vasomotor symptoms, and baseline hormone levels are significant modifiers of the effects of HT on serum estrogens. These data provide a reference point for serum hormone response to HT, demonstrate that this response is similar for EPT and ET, and suggest a larger response to HT in women with low endogenous levels.
